Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123315 | 0.83 | ALDH1A1 (0.57) | HTTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL3467997 | 0.80 | CHRM1 (0.43) | — | |
| SCHEMBL3467999 | 0.80 | CHRM1 (0.43) | — | |
| SCHEMBL1918784 | 0.78 | ALDH1A1 (0.54) | HTTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL19742164 | 0.74 | DRD2 (0.46) | HTTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL29226874 | 0.73 | MPO (0.47) | HTTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL29226876 | 0.73 | MPO (0.47) | HTTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL600719 | 0.73 | ALDH1A1 (0.38) | HTTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL17911484 | 0.73 | HTT (0.42) | HTTALDH1A1CYP3A4ALOX15TDP1 | |
| SCHEMBL17911485 | 0.73 | HTT (0.42) | HTTALDH1A1CYP3A4ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853241-B2 | Biaryl substituted azabicyclic alkane derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2280010-B1 | Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators | ABBOTT LAB (US) | 2012-12-19 | — | — | EP | disclosed |
| EP-2431368-A1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | Abbott Laboratories (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-2018380-B1 | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LAB (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110124676-A1 | BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2011-05-26 | — | — | US | disclosed |
| US-7902222-B2 | Biaryl substituted azabicyclic alkane derivatives | ABBOTT LABORATORIES (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2280010-A2 | Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators | Abbott Laboratories (US) | 2011-02-02 | — | — | EP | disclosed |
| US-7872017-B2 | Fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20090192186-A1 | BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-07-30 | — | — | US | disclosed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192186-A1 | BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, AADAC, ALK | POLB 853/4885HTT 2106/4885ALDH1A1 128/4885 |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, BMP2, ALKBH2 | POLB 727/4885HTT 1970/4885ALDH1A1 694/4885 |
| US-20110124676-A1 | BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, AADAC, ALK | POLB 853/4885HTT 2106/4885ALDH1A1 128/4885 |
| US-20100305089-A1 | Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives | MALT1, BMP2, ALKBH2 | POLB 727/4885HTT 1970/4885ALDH1A1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.